Literatuur
- Armstrong et al. Everolimus versus sunitinib for patients with metastastic non-clear cell renal cell carcinom (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol. 2016; 17(3):378-88
- Choueiri et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomized, open-label, phase 3 trial. Lancet Oncology. 2016; 17:917-27
- Choueiri et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. New England Journal of Medicine. 2021; 384:829-41
- Choueiri et al. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. Lancet Oncology. 2023 Mar; 24(3):228-238
- Choueiri et al. Overall survival with adjuvant pembrolizumab in renal-cell carcinoma. New England Journal of Medicine. 2024; 390(15):1359-71
- Escudier et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preferences for pazopanib versus sunitinib in patients with metastastic renal cell carcinoma: PISCES study. J. of Clin. Oncol. 2014; 32(14):1412-18
- Fitzgerald et al. Cabozantinib plus nivolumab in patients with non-clear cell renal cell carcinoma: updated results from a phase 2 trial. Eur Urol 2024; 86(2):90-94
- Heng et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncology 2013; 14(2):141-148
- Motzer et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New England Journal of Medicine. 2007; 356(2):115-24
- Motzer et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial. Lancet. 2008; 372:449-56
- Motzer et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. New England Journal of Medicine. 2013; 369:772-31
- Motzer et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. New England Journal of Medicine. 2015; 373(19):1803-1913
- Motzer et al. Nivolumab plus ipilimumab versus sunitinib in advance renal-cell carcinoma. New England Journal of Medicine. 2018; 378(14):1277-90
- Motzer et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. New England Journal of Medicine. 2021; 384(14):1289-300
- Rini et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. New England Journal of Medicine. 2019; 380:1116-27
- Yip et al. Outcomes of metastatic chromophobe renal cell carcinoma (chRCC) in the targeted therapy era: results from the international metastatic renal cell cancer database consortium (IMDC). Kidney Cancer. 2021; 41-47
- Albiges et al. Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear cell renal carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2023; 224(8): 881-91
Commissie BOM adviezen
Ga naar de commissie BOM adviezen over niercelcarcinoom.
Richtlijnen
Ga naar de richtlijn Renal cell carcinoma van de ESMO.
Ga naar de richtlijn Renal cell carcinoma van de EAU.
Ga naar de richtlijn Niercelcarcinoom in de FMS richtlijnendatabase.
Ga naar de richtlijn Niercelcarcinoom van VKGN - StOET.